Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (27)

I-01Leon Aarons

Population Pharmacokinetic Analysis of Ropivacaine and its Metabolite PPX from Pooled Data in Neonates, Infants and Children

Wednesday 10:15-11:45

I-04Hesham Al-Sallami

A semi-mechanistic model for estimating fat free mass in children

Wednesday 10:15-11:45

I-27Marion Bouillon-Pichault

Pharmacokinetic design optimization in children and estimation of maturation parameters: example of cytochrome P450 3A4

Wednesday 10:15-11:45

I-36Massimo Cella

Implementation of Pharmacokinetic Bridging for Drug Combinations in Children

Wednesday 10:15-11:45

I-38Pascal Chanu

A dose selection rationale based on hemodynamics for sildenafil in pediatric patients with pulmonary arterial hypertension (PAH)

Wednesday 10:15-11:45

I-48Karina Blei

Evaluation of a PBPK Model for Preterm Neonates by Predicting Paracetamol Pharmacokinetics

Wednesday 10:15-11:45

II-05

Design optimisation of a pharmacokinetic study in the paediatric development of a drug

Wednesday 14:55-16:10

II-08Esther Encinas

Fentanyl pharmacokinetic and pharmacodynamic (PK/PD) estimation in neonates and infants using allometric and ontogeny methods

Wednesday 14:55-16:10

II-12David Fabre

Population Pharmacokinetics of Alfusozin in children and adolescents

Wednesday 14:55-16:10

II-32Andreas Velsing Groth

Predicting paediatric PK in order to investigate it

Wednesday 14:55-16:10

II-39Anna-Karin Hamberg

Predictions of warfarin exposure and INR response in children

Wednesday 14:55-16:10

II-41

Population K-PD Model of Sodium Nitroprusside in Neonates and Children During Anesthesia or Sedation

Wednesday 14:55-16:10

II-45Ibrahim Ince

Population PK of midazolam from preterm neonates to adults, a maturation model

Wednesday 14:55-16:10

II-56Nastya Kassir

An Optimal Sampling Strategy for Tacrolimus in Pediatric Liver Transplant Recipients Based on a Population Pharmacokinetic Model

Wednesday 14:55-16:10

II-63Sung Eun Kim

Population Pharmacokinetics of Theophylline in Premature Korean Infants

Wednesday 14:55-16:10

II-64Holly Kimko

Disease-Drug Model of Methylphenidate (MPH) in Children with Attention Deficit Hyperactivity Disorder Via Longitudinal Meta-analysis

Wednesday 14:55-16:10

III-03Elke Krekels

Maturation of glucuronidation; a system specific property

Thursday 09:50-11:05

III-20Amelie Marsot

Population pharmacokinetics of Phenobarbital in neonates and infants.

Thursday 09:50-11:05

III-45

Dried Blood Spots and Sparse Sampling: A perfect combination for minimally invasive PK/PD studies in children

Thursday 09:50-11:05

III-53Chiara Piana

Impact of non-adherence to antiretroviral therapy in HIV-infected children

Thursday 09:50-11:05

IV-10

Dose Selection of Dolutegravir (DTG, S/GSK1349572) in Pediatric Studies

Thursday 15:05-16:20

IV-31Wanchana Ungphakorn

Population Pharmacokinetics and Use of Monte Carlo Simulation To Determine Optimal Dosing Regimen of Oral Ciprofloxacin in Paediatric Patients with Severe Malnutrition

Thursday 15:05-16:20

IV-33Pyry Välitalo

Pharmacokinetics of Oxycodone in Labouring Women With Preliminary Estimates of Neonatal Exposure

Thursday 15:05-16:20

IV-39Sven van Dijkman

Optimal design for a dexmedetomidine pharmacokinetic trial in mechanically ventilated neonates with single organ respiratory failure.

Thursday 15:05-16:20

IV-44Katarina Vučićević

Population Pharmacokinetic Modelling of Amikacin in Neonates

Thursday 15:05-16:20

IV-46Chenguang Wang

The allometric exponent for propofol clearance varies with age

Thursday 15:05-16:20

IV-64

Individualized therapy and Bayesian estimator of ganciclovir exposure after oral administration of valganciclovir in pediatric renal transplant patients

Thursday 15:05-16:20